202 related articles for article (PubMed ID: 26199091)
1. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Morfouace M; Cheepala S; Jackson S; Fukuda Y; Patel YT; Fatima S; Kawauchi D; Shelat AA; Stewart CF; Sorrentino BP; Schuetz JD; Roussel MF
Cancer Res; 2015 Sep; 75(18):3879-89. PubMed ID: 26199091
[TBL] [Abstract][Full Text] [Related]
2. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
5. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
7. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
8. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
9. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
10. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
11. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
Hu C; Li H; Li J; Zhu Z; Yin S; Hao X; Yao M; Zheng S; Gu J
Carcinogenesis; 2008 Dec; 29(12):2289-97. PubMed ID: 18820285
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
13. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
14. Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.
Kowalski P; Farley KM; Lage H; Schneider E
Anticancer Res; 2004; 24(4):2231-5. PubMed ID: 15330166
[TBL] [Abstract][Full Text] [Related]
15. Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Robey RW; Steadman K; Polgar O; Morisaki K; Blayney M; Mistry P; Bates SE
Cancer Res; 2004 Feb; 64(4):1242-6. PubMed ID: 14973080
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.
Pál A; Méhn D; Molnár E; Gedey S; Mészáros P; Nagy T; Glavinas H; Janáky T; von Richter O; Báthori G; Szente L; Krajcsi P
J Pharmacol Exp Ther; 2007 Jun; 321(3):1085-94. PubMed ID: 17347325
[TBL] [Abstract][Full Text] [Related]
17. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
[TBL] [Abstract][Full Text] [Related]
19. Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter.
Telbisz Á; Hegedüs C; Özvegy-Laczka C; Goda K; Várady G; Takáts Z; Szabó E; Sorrentino BP; Váradi A; Sarkadi B
Eur J Pharm Sci; 2012 Jan; 45(1-2):101-9. PubMed ID: 22115866
[TBL] [Abstract][Full Text] [Related]
20. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
Ivnitski-Steele I; Larson RS; Lovato DM; Khawaja HM; Winter SS; Oprea TI; Sklar LA; Edwards BS
Assay Drug Dev Technol; 2008 Apr; 6(2):263-76. PubMed ID: 18205550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
